CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--May 2, 2017--
Aptar Pharma and Kali Care have announced that they entered into a
partnership in order to address the challenge of monitoring adherence in
ophthalmic clinical trials. The combination of Aptar Pharma’s ophthalmic
device expertise, and Kali Care’s ground-breaking digital monitoring
system for ophthalmic medications, is likely to have a significant
impact in reducing the costs and complexity of ophthalmic clinical
trials.
Kali Care, a Silicon Valley-based technology company, provides a
revolutionary sensor technology which allows clinicians to replace
adherence assumptions in clinical trials with collected real-time data.
This represents the latest step for Aptar Pharma in the development of
drug delivery devices and collaborations in the connected health space.
Combining the Silicon Valley Spirit with Proven Expertise in Drug
Delivery Systems
Aptar Pharma has been setting the standard for the drug delivery
industry for decades. This strategic collaboration once again underlines
the company’s continuous efforts in breaking new ground in innovative
healthcare technologies.
Sina Fateh, MD, Founder and CEO of Kali Care, explained that because
Aptar Pharma is well-respected for its proven regulatory expertise, this
will help his company move forward through approval and compliance
processes.
Aptar Pharma’s ability to support complex projects and meet the
challenging and changing regulatory requirements was recently
demonstrated by their
collaboration with Allergan on launching the first FDA-approved
prescription preservative-free ophthalmic multidose product (Restasis
MultiDose™).
Meeting the Needs of Patients and Clinicians
Using eye drops as a drug delivery system has its own set of challenges
which must be recognized and addressed at the clinical level. Clinical
trials benefit from more accurate and timely data collection and
management.
For ophthalmologists, the ability to see the medication adherence score
of patients with glaucoma is a powerful tool in managing treatment plans.
Enhancing Clinical Information
Kali Care has developed the first digital monitoring system for
ophthalmic medications. Kali Care’s monitoring technology integrates
smart sensors, data analytics and cloud services.
With soaring clinical trial costs and complexity, the biopharmaceutical
industry is constantly seeking new approaches to improve efficiency and
productivity. In clinical trials, the Kali Care system replaces usage
assumptions and self-reporting related to medication adherence. This can
result in shorter and more efficient clinical trials. The Kali Care
Adherence Score provides critical information for explaining the
incongruity between recommended treatment and actual treatment outcomes.
Staying Ahead of the Market
Combined with the recent breakthrough of Aptar Pharma’s ophthalmic drug
delivery systems, Kali Care’s revolutionary sensor technology opens new
opportunities for the monitoring of patient adherence.
In a joint statement, Salim Haffar, President of Aptar Pharma, and Sina
Fateh, MD, highlighted the advantages associated with combining
unrivalled microbiological safety and revolutionary sensor technology,
“Clinicians are now able to rely on objective and accurate data. Aptar
Pharma’s leading dispensing technologies combined with Kali Care’s smart
sensors, data analytics and cloud services will help make clinical
trials more efficient and effective. This allows ophthalmologists to
improve risk strategies to distinguish patients requiring minimal
support from those who require closer monitoring.”
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global
supplier of a broad range of innovative dispensing and sealing solutions
for the beauty, personal care, home care, prescription drug, consumer
health care, injectables, food and beverage markets. AptarGroup is
headquartered in Crystal Lake, Illinois, with manufacturing facilities
in North America, Europe, Asia and South America. For more information,
visit aptar.com/pharma.
This press release contains forward-looking statements. Words such as
“expects,” “anticipates,” “believes,” “estimates,” “future” and other
similar expressions or future or conditional verbs such as “will,”
“should,” “would” and “could” are intended to identify such
forward-looking statements. Forward-looking statements are made pursuant
to the safe harbor provisions of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934 and are
based on our beliefs as well as assumptions made by and information
currently available to us. Accordingly, our actual results may differ
materially from those expressed or implied in such forward-looking
statements due to known or unknown risks and uncertainties that exist in
our operations and business environment. Additionally, forward-looking
statements include statements that do not relate solely to historical
facts, such as statements which identify uncertainties or trends,
discuss the possible future effects of current known trends or
uncertainties or which indicate that the future effects of known trends
or uncertainties cannot be predicted, guaranteed or assured. For
additional information on these and other risks and uncertainties,
please see our filings with the Securities and Exchange Commission,
including the discussion under “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation
to update any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502006628/en/
Source: AptarGroup, Inc.
Media Contact:
Carolyn Penot
Aptar
Pharma
+33 1 39 17 20 38
carolyn.penot@aptar.com
or
Investor
Relations Contact:
Matthew DellaMaria
AptarGroup,
Inc.
+1 815 477 0424
matt.dellamaria@aptar.com